(RTTNews) - Zai Lab Limited (ZLAB) and Novocure (NVCR) announced the LUNAR study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in overall survival over standard therapies alone. The LUNAR study is a randomized study evaluating the safety and efficacy of Tumor Treating Fields together with standard therapies for stage 4 non-small cell lung cancer following progression.
Tumor Treating Fields or TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
Novocure plans to file a Premarket Approval application with the FDA in the second half of 2023. Novocure also plans to file for a CE Mark in the European Union concurrently with the FDA submission.
For More Such Health News, visit rttnews.com.
Shares of Novocure are up 68% in pre-market trade on Thursday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
